DNA binding-independent anti-proliferative action of benzazolo[3,2-alpha]quinolinium DNA intercalators.
The proposed mechanism of action of the antineoplastic drug 3-nitrobenzothiazolo[3,2-alpha]quinolinium chloride (NBQ-2) involves its interaction with DNA by intercalation and inhibition of topoisomerase II activity by arresting the enzyme in a covalent cleavage complex. In an attempt to identify some structural determinants for activity and develop a molecular structure/cytotoxicity correlation, four new structural analogs of the antitumor NBQ-2 were prepared and their cytotoxic activity and DNA binding properties were investigated. The cytotoxic activity was evaluated against six different human tumor cell lines: U937, K-562, HL-60, HT-29, HeLa, and A431. The results showed that these new drugs elicit pronounced cytotoxic effects against U937, K-562, HL-60 and A431 while HeLa and HT-29 were less sensitive to the new drugs. This apparent selectivity was different to that of m-AMSA, a drug currently used for cancer treatment. Since the interaction of NBQ-2 to DNA by intercalation has been proposed as the initial step leading to its antineoplastic activity, DNA binding and changes in DNA contour length induced by the new NBQ-2 structural analogs were also investigated using calf thymus and human DNA. The drug, 7-(1-propenyl)-3-nitrobenzimidazolo[3,2-alpha]quinolinium chloride (NBQ-59) was the most cytotoxic agent of the analog series (IC50 = 16 microM for HL-60 cells), however, it demonstrated the weakest binding to DNA (Kint = 0.9 x 10[5] M-1 for calf thymus DNA). NBQ-59 was also found to be a poor intercalator into the DNA double helix. Therefore, our results suggest that DNA binding is not the primary mechanism of drug action for this family of compounds. In addition structural determinants important for cytotoxicity of the benzazolo quinolinium chlorides were suggested by our results. In particular, the nitro group in the 3 position does not seem to be necessary for bioactivity, while substitutions in the benzazolo moiety have striking effects on the biological activity of the drugs.
Vivas-Mejía
P E
PE
Department of Chemistry, Biotesting Center, University of Puerto Rico, Río Piedras Campus, San Juan 00931-3346, USA.
Rodríguez-Cabán
J L
JL
Díaz-Velázquez
M
M
Hernández-Pérez
M G
MG
Cox
O
O
Gonzalez
F A
FA
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000633:toxicity; D002294:Carcinoma, Squamous Cell; D004247:DNA / Q000187:drug effects / Q000378:metabolism*; D006131:Growth Inhibitors / Q000494:pharmacology* / Q000633:toxicity; D018922:HL-60 Cells; D019073:HT29 Cells; D006367:HeLa Cells; D006801:Humans; D007364:Intercalating Agents / Q000494:pharmacology* / Q000633:toxicity; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive; D016403:Lymphoma, Large B-Cell, Diffuse; D011806:Quinolinium Compounds / Q000494:pharmacology* / Q000633:toxicity; D014407:Tumor Cells, Cultured; D014783:Viscosity
D000970:Antineoplastic Agents; D006131:Growth Inhibitors; D007364:Intercalating Agents; D011806:Quinolinium Compounds; C038668:3-nitrobenzothiazolo(3,2-a)quinolinium; D004247:DNA